OncoCyte Corporation with ticker code (OCX) have now 7 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 8 and 2 with a mean TP of 4.71. With the stocks previous close at 5.1 this indicates there is a potential downside of -7.6%. The 50 day MA is 2.98 and the 200 moving average now moves to 1.88. The market capitalisation for the company is $429m. Visit the company website at: http://www.oncocyte.com
OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.